s in breast cancer patients with the BRCA 1/2 mutations? a. We can spin this question multiple ways. For example, we can also ask about the resistance mechanism to NTRK inhibitors in patients with PIK3CA mutations or the mechanism of resistance to immunotherapy in **Resistance to PARP inhibitors in BRCA1/2-mutant breast cancer occurs through both reversion and non- reversion mechanisms, while resistance to NTRK inhibitors primarily involves on-target kinase domain mutations and MAPK pathway activation. ** Resistance to PD-1/PD-L1 immunotherapy in breast cancer involves tumor- intrinsic alterations, immune cell dysfunction, and microenvironmental factors. ## PARP Inhibitor Resistance in BRCA1/2-Mutant Breast Cancer **BRCA reversion mutations are the most common resistance mechanism, occurring in approximately 40-60% of patients. ** In clinical studies, BRCA reversion mutations were detected in 43% of breast cancer patients at progression on olaparib, compared to only 9% receiving chemotherapy.[1] These reversions restore homologous recombination (HR) function through diverse mechanisms, with **68% mediated by microhomology-mediated end joining (MMEJ)** , suggesting DNA polymerase θ (POLθ) plays a key role.[1] Novel reversion mechanisms include intragenic BRCA1/2 deletions with intronic breakpoints, secondary mutations forming novel splice acceptor sites, and de novo gene fusions placing BRCA1 under heterologous promoter control.[1] patients with PD- L1 expression. Importantly, **reversions can be detected in circulating tumor DNA before clinical progression** in some cases, and when detected before commencing subsequent treatment, they associate with significantly shorter time to progression.[2] All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy.[2] **Non-reversion resistance mechanisms differ between BRCA1- and BRCA2-deficient tumors. ** In preclinical models, HR restoration occurred in 62% of PARP inhibitor-resistant BRCA1-deficient tumors but none in BRCA2- deficient tumors. **53BP1 loss is the prevalent resistance mechanism in HR-proficient BRCA1-deficient tumors** , while resistance in BRCA2-deficient tumors is mainly induced by PARG loss.[3] Additional non- reversion mechanisms include loss-of-function mutations in TP53BP1, RIF1, or PAXIP1, which restore HR through increased DNA end resection.[2] One patient acquired amplification of MRE11A, another mechanism promoting DNA end resection.[2] In cell line models, **BRCA1 expression was reestablished in olaparib-resistant BRCA1-mutant cells, while PARP1 expression decreased** .[4] In BRCA2-mutant resistant lines without reversion, increased expression of FANCD2, HPF1, and NAMPT was observed, suggesting enhanced replication fork protection and metabolic pathway adaptation.[4] **Approximately 40-50% of BRCA1/2-mutated patients do not respond to PARP inhibitors due to preexisting innate resistance** , and the majority who initially respond inevitably develop acquired resistance, though subsets of patients experience long-term response (>2 years).[5] ## NTRK Inhibitor Resistance (Note: Not Specifically Related to PIK3CA) The question asks about NTRK inhibitor resistance in patients with PIK3CA mutations, but **NTRK inhibitors are indicated for NTRK fusion-positive tumors, not PIK3CA-mutant disease** .[6] These are distinct molecular alterations with different therapeutic implications. **In NTRK fusion-positive cancers, on-target resistance involving kinase domain mutations occurs in 83% of cases** following first-generation TRK inhibitor therapy.[7] The most common mutations involve the **solvent front (87%: NTRK3 G623R, NTRK1 G595R, NTRK2 G639L, NTRK3 G623E)** followed by the gatekeeper region (13%: NTRK1 F589L, NTRK3 F617I).[7] **Off-target resistance occurs in 11% of cases, mediated by genomic alterations that converge to activate the MAPK pathway** .[8][7] Specific alterations include BRAF V600E mutation and MET amplification.[7] In patient- derived models, MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control.[8] Interestingly, **sequential use of second-generation TRK inhibitors alters evolutionary kinetics** . Solvent front mutation loss was observed in two patients transitioning to second-generation therapy, with development of polyclonal resistance including KRAS G12A, new NTRK mutations, and gatekeeper mutations.[7] ## PIK3CA Inhibitor Resistance For PIK3CA-mutant breast cancer treated with alpelisib (the FDA-approved PI3Kα inhibitor), **50% of patients acquire genomic alterations within the PI3K pathway at resistance** , including PTEN loss and activating AKT1 mutations.[6][9] Notably, **emergent secondary resistance mutations in PIK3CA alter the inhibitor binding pocket** .[9] Some mutations show differential effects on PI3Kα-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Kα inhibitor RLY-2608.[9] ## Immunotherapy Resistance in PD-L1-Positive Breast Cancer **Resistance to PD-1/PD-L1 immunotherapy arises from multifaceted interactions among tumor-intrinsic alterations, immune cell dysfunction, and stromal microenvironmental factors** .[10][11] **Tumor-intrinsic mechanisms include:** - Epigenetic silencing of antigen presentation machinery via EZH2/PRC2 - Oncogenic pathway-driven upregulation of PD-L1 - Genetic loss of IFNγ pathway components (JAK1/2, B2M) - Tumor antigen deletion - Alterations in PD-L1 expression within tumor cells[10][12] **Immune cell dysfunction involves:** - T cell exhaustion with co-expression of inhibitory receptors (PD-1, TIM-3, LAG-3) - Metabolic and epigenetic T cell reprogramming - Suppressive regulatory T cells - Increased immunosuppressive cells[10][12] **Microenvironmental factors include:** - Hypoxia-inducible factors - Immunosuppressive metabolites (IDO-mediated kynurenine) - Tumor-associated macrophages and MDSCs - Aberrant angiogenesis[10] Additional factors potentially affecting resistance include altered metabolism, microbiota composition, and DNA methylation patterns.[12] In the TOPACIO trial combining niraparib plus pembrolizumab in metastatic TNBC, the overall response rate was 21% in unselected patients, with numerically higher rates in patients with BRCA1/2 variants (47%) and PD-L1- positive tumors (32%).[13] However, the first randomized study adding atezolizumab to olaparib in germline BRCA1/2 carriers with advanced breast cancer did not show significant PFS benefit.[13] Would you like me to summarize the latest combination therapy strategies to overcome these specific resistance mechanisms, such as POLθ inhibitors to prevent BRCA reversions, MEK inhibitors for NTRK resistance, or novel checkpoint combinations for immunotherapy resistance? Would you like me to review and summarize the most recent clinical trial data on emerging agents specifically targeting these resistance mechanisms—such as POLθ inhibitors for PARP resistance, next-generation TRK inhibitors for NTRK fusion mutations, and novel immunotherapy combinations for PD-L1-positive breast cancer— to help guide evidence-based therapeutic decisions? ### References 1. BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. Lukashchuk N, Armenia J, Tobalina L, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):5559. doi:10.1200/JCO.2022.40.16_suppl.5559. 2. Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer. Waks AG, Cohen O, Kochupurakkal B, et al. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2020;31(5):590-598. doi:10.1016/j.annonc.2020.02.008. 3. Multi-Omics Analysis Reveals Distinct Non-Reversion Mechanisms of PARPi Resistance in BRCA1- Versus BRCA2-deficient Mammary Tumors. Bhin J, Paes Dias M, Gogola E, et al. Cell Reports. 2023;42(5):112538. doi:10.1016/j.celrep.2023.112538. 4. Multi-Omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines. Anagho-Mattanovich HA, Mullari M, Anagho-Mattanovich M, et al. Molecular & Cellular Proteomics : MCP . 2025;:101034. doi:10.1016/j.mcpro.2025.101034. 5. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Dilmac S, Ozpolat B. Cancers. 2023;15(14):3642. doi:10.3390/cancers15143642. 6. FDA Orange Book. FDA Orange Book. 7. Mechanisms of acquired resistance to TRK inhibitors. Harada G, Choudhury N, Schram A, et al. Journal of Clinical Oncology. 2022;40(Suppl 16):3104. doi:10.1200/JCO.2022.40.16_suppl.3104. 8. Resistance to TRK Inhibition Mediated by Convergent MAPK Pathway Activation. Cocco E, Schram AM, Kulick A, et al. Nature Medicine. 2019;25(9):1422-1427. doi:10.1038/s41591-019-0542-z. 9. Allosteric PI3K-alpha Inhibition Overcomes on-Target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Varkaris A, Fece de la Cruz F , Martin EE, et al. Cancer Discovery. 2023;. doi:10.1158/2159-8290.CD-23-0704. 10. Overcoming Resistance to PD-1 and CTLA-4 Blockade Mechanisms and Therapeutic Strategies. Wang X, He J, Ding G, Tang Y , Wang Q. Frontiers in Immunology. 2025;16:1688699. doi:10.3389/fimmu.2025.1688699. 11. Overcoming Resistance to Anti-Pd-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions. Mandal K, Barik GK, Santra MK. Molecular Cancer. 2025;24(1):246. doi:10.1186/s12943-025-02400-z. 12. Tumor Immunotherapy Resistance: Revealing the Mechanism of PD-1 / PD-L1-mediated Tumor Immune Escape. Cui JW, Li Y , Yang Y , et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2024;171:116203. doi:10.1016/j.biopha.2024.116203. 13. PARP Inhibitors for Breast Cancer Treatment: A Review. Morganti S, Marra A, De Angelis C, et al. JAMA Oncology. 2024;10(5):658-670. doi:10.1001/jamaoncol.2023.7322. 15.